Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

HCRN GI19-405

A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

Status: Open to Accrual

Learn more:

Abstracts/Posters/Presentations:

  • AR He, AY Kim, BM Toskich, K Mody, K Kim, S Stein, L Goyal, TA Abrams, D Brown, LW Goff, RD Kim, N Parikh, T Sandow, D Johnson, RV Iyer, M Petroziello, SS Krishnamurthi, C Martin, Y Jiang, N Akhter. A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC). Presented as a Trials in Progress Poster at the 2021 Gastrointestinal Cancers Symposium. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.